摘要
恩沃利单抗作为全球首个皮下给药的细胞程序性死亡-配体1(PD-L1)抑制剂,在微卫星高度不稳定(MSI-H)或错配修复基因缺陷型(dMMR)的多种实体瘤(肺癌、结直肠癌、胃癌、子宫内膜癌等)的治疗中均显示出良好的抗肿瘤活性及安全性。本文将从恩沃利单抗的药物结构与作用机制、相关临床研究、安全性与不良反应等方面作一综述。
As the first programmed death-ligand 1(PD-L1)inhibitor of subcutaneous administration in the world,envafolimab shows good anti-tumor activity and safety in the treatment of many kinds of solid tumors(lung cancer,colorectal cancer,gastric cancer,endometrial cancer,etc.)with microsatellite instability-high(MSI-H)or deficiency of mismatch repair gene(dMMR).This article will review the drug structure and mechanism of action,related clinical studies,safety and adverse reactions of envafolimab.
作者
赵丽丽
龙麟
梁欣
王芸
庄珊
田金
肖军
ZHAO Lili;LONG Lin;LIANG Xin;WANG Yun;ZHUANG Shan;TIAN Jin;XIAO Jun(Oncology Center;Outpatient Department,Qingdao Hiser Hospital Affiliated to Qingdao University(Qingdao Traditional Chinese Medicine Hospital),Shandong Qingdao 266033,China;Department of Radiotherapy,Qilu Hospital of Shandong University(Qingdao),Shandong Qingdao 266000,China.)
出处
《现代肿瘤医学》
CAS
2024年第6期1154-1158,共5页
Journal of Modern Oncology
基金
山东省中医药科技项目(编号:2020Z31)
吴阶平医学基金会临床科研专项基金(编号:320.6750.2021-2-93)。
